PCRX vs. PRGO, SUPN, OMER, NKTR, ASMB, CPIX, LLY, JNJ, ABBV, and MRK
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry.
Pacira BioSciences vs.
Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
In the previous week, Pacira BioSciences had 16 more articles in the media than Perrigo. MarketBeat recorded 24 mentions for Pacira BioSciences and 8 mentions for Perrigo. Perrigo's average media sentiment score of 0.82 beat Pacira BioSciences' score of 0.05 indicating that Perrigo is being referred to more favorably in the news media.
Perrigo has a net margin of -3.64% compared to Pacira BioSciences' net margin of -13.07%. Pacira BioSciences' return on equity of 13.42% beat Perrigo's return on equity.
99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 0.7% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Pacira BioSciences currently has a consensus price target of $22.78, indicating a potential downside of 11.51%. Perrigo has a consensus price target of $35.00, indicating a potential upside of 38.81%. Given Perrigo's stronger consensus rating and higher probable upside, analysts plainly believe Perrigo is more favorable than Pacira BioSciences.
Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Pacira BioSciences received 54 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 71.43% of users gave Pacira BioSciences an outperform vote while only 66.35% of users gave Perrigo an outperform vote.
Pacira BioSciences has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Summary
Pacira BioSciences beats Perrigo on 12 of the 18 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
This page (NASDAQ:PCRX) was last updated on 2/21/2025 by MarketBeat.com Staff
